Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Advanced cervical cancer
BRCA1
Olaparib
PARP inhibitor
Precision oncology
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
02
04
2020
accepted:
01
03
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer. Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic BRCA1 germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2 years stable disease; pathological report showed complete pathological response, and 12 months follow-up showed no recurrence. Poly(ADP-ribose) polymerase inhibitors could be an alternative maintenance treatment for patients with persistent advanced cervical cancer previously treated with platinum, especially when familial history of cancers is reported. Clinical trials using poly(ADP-ribose) polymerase inhibitors for advanced cervical cancer are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer.
CASE PRESENTATION
METHODS
Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic BRCA1 germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2 years stable disease; pathological report showed complete pathological response, and 12 months follow-up showed no recurrence.
CONCLUSION
CONCLUSIONS
Poly(ADP-ribose) polymerase inhibitors could be an alternative maintenance treatment for patients with persistent advanced cervical cancer previously treated with platinum, especially when familial history of cancers is reported. Clinical trials using poly(ADP-ribose) polymerase inhibitors for advanced cervical cancer are warranted.
Identifiants
pubmed: 33888155
doi: 10.1186/s13256-021-02767-9
pii: 10.1186/s13256-021-02767-9
pmc: PMC8063354
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Phthalazines
0
Piperazines
0
Bevacizumab
2S9ZZM9Q9V
olaparib
WOH1JD9AR8
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Références
Int J Gynecol Cancer. 2015 Mar;25(3):484-92
pubmed: 25594147
J Clin Oncol. 2019 Sep 20;37(27):2449-2459
pubmed: 31403862
Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83
pubmed: 28881916
Sci Rep. 2017 Oct 9;7(1):12876
pubmed: 28993682
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:131-136
pubmed: 30306576
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):153-160
pubmed: 27838135
Mol Cell Biochem. 2009 Jan;320(1-2):15-23
pubmed: 18695944
Crit Rev Oncol Hematol. 2016 Dec;108:164-174
pubmed: 27931835
Am J Pathol. 2011 Mar;178(3):946-55
pubmed: 21356345
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103
pubmed: 17161167
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Oncotarget. 2015 Sep 29;6(29):26995-7007
pubmed: 26336991
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2201-6
pubmed: 20133863
Ann Oncol. 2017 Mar 1;28(3):505-511
pubmed: 27998970
Pathol Oncol Res. 2012 Oct;18(4):929-37
pubmed: 22454210
Drugs R D. 2020 Jun;20(2):55-73
pubmed: 32215876
Target Oncol. 2019 Dec;14(6):657-679
pubmed: 31625002
Curr Treat Options Oncol. 2016 Mar;17(3):12
pubmed: 26931795
Gynecol Oncol. 2019 Oct;155(1):144-150
pubmed: 31434613
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Lett. 1981 Dec;14(3):227-36
pubmed: 6277470